Royce & Associates LP Has $11.20 Million Stock Position in Elanco Animal Health Incorporated $ELAN

Royce & Associates LP reduced its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 17.9% in the 4th quarter, HoldingsChannel reports. The firm owned 494,926 shares of the company’s stock after selling 107,638 shares during the period. Royce & Associates LP’s holdings in Elanco Animal Health were worth $11,200,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Independent Advisor Alliance lifted its position in Elanco Animal Health by 364.5% during the third quarter. Independent Advisor Alliance now owns 98,025 shares of the company’s stock worth $1,974,000 after acquiring an additional 76,920 shares during the last quarter. State of Michigan Retirement System acquired a new stake in Elanco Animal Health during the third quarter worth approximately $2,383,000. Teachers Retirement System of The State of Kentucky acquired a new stake in Elanco Animal Health during the third quarter worth approximately $2,215,000. JPMorgan Chase & Co. lifted its position in Elanco Animal Health by 266.4% during the third quarter. JPMorgan Chase & Co. now owns 1,918,336 shares of the company’s stock worth $38,635,000 after acquiring an additional 1,394,839 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp acquired a new stake in Elanco Animal Health during the third quarter worth approximately $1,444,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Stock Up 3.9%

NYSE ELAN opened at $23.71 on Thursday. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. Elanco Animal Health Incorporated has a 1-year low of $12.97 and a 1-year high of $27.72. The company has a 50 day moving average of $23.00 and a 200-day moving average of $23.30. The company has a market cap of $11.84 billion, a price-to-earnings ratio of -47.41, a PEG ratio of 2.46 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. During the same period in the previous year, the business earned $0.37 earnings per share. The firm’s quarterly revenue was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities research analysts expect that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Elanco Animal Health news, insider Rajeev A. Modi purchased 4,911 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was bought at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the transaction, the insider owned 160,812 shares in the company, valued at approximately $3,272,524.20. This represents a 3.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was acquired at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the transaction, the chief executive officer owned 171,971 shares of the company’s stock, valued at $3,454,897.39. This represents a 2.98% increase in their position. The disclosure for this purchase is available in the SEC filing. 1.14% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Citigroup raised their price objective on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Wall Street Zen downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Morgan Stanley raised their price objective on shares of Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. UBS Group restated a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Finally, KeyCorp raised their price objective on shares of Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.20.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.